Evidence map›Paper›PMID 38597986›Full record

Trial reportInternational journal of hematology2024

A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.

Koji Izutsu, Hisashi Kato, Naohiro Sekiguchi, Tomoaki Fujisaki, Toshiro Kawakita, Naoshi Obara, Kosei Matsue, Mitsutaka Nishimoto, Tomoyoshi Hatayama, Mitsuo Inagaki and 1 more

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. kizutsu@ncc.go.jp.ORCID http://orcid.org/0000-0001-9129-8057
Hisashi KatoDepartment of Hematology and Oncology, Osaka University Hospital, Osaka, Japan.
Naohiro SekiguchiDivision of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
Tomoaki FujisakiDepartment of Internal Medicine, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Naoshi ObaraDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Kosei MatsueDepartment of Hematology, Kameda General Hospital, Kamogawa, Japan.
Mitsutaka NishimotoDepartment of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Tomoyoshi HatayamaResearch and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.
Mitsuo InagakiResearch and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.
Ei FujikawaResearch and Development Division, Janssen Pharmaceutical K.K, Tokyo, Japan.
Kameda Medical Center · JPKumamoto Medical Center · JPMatsuyama Red Cross Hospital · JPNational Cancer Centre Japan · JPNational Hospital Organization · JPOsaka Metropolitan University · JPOsaka University Hospital · JPUniversity of Tsukuba Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ibrutinib is a first-in-class Bruton kinase inhibitor against B-cell neoplasms including Waldenström macroglobulinemia (WM). This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m

Indexed as

AdenineAntineoplastic Combined Chemotherapy ProtocolsPiperidinesRituximabWaldenstrom MacroglobulinemiaAgedAged, 80 and overEast Asian PeopleFemaleHumansJapanMaleMiddle AgedPyrazolesPyrimidinesTreatment OutcomeAdenineibrutinibPiperidinesPyrazolesPyrimidinesRituximabIbrutinibJapanese patientsRituximabWaldenstrom’s macroglobulinemia

Identifiers

PMID38597986
PMCPMC11229445
OpenAlexW4394693119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.